 |
|
|
| |
8 weeks of Glecaprevir/Pibrentasvir is highly effective in patients with genotype 3 hepatitis C related cirrhosis, irrespective of the presence of clinically significant portal hypertension
|
| |
| |
EASL 2025 May 7-10 Amsterdam
Fiona Marra1, Alison Boyle1, Erica Peters1, Helen Cairns1, Rachael Swann1, Janice Mcavennie1, Elaine Reilly1, Stephen Barclay1.
1NHS Greater Glasgow & Clyde, Glasgow, United Kingdom
|
| |
|
|
|
|
|
